| Name | Thames Ventures Vct 2 Healthcare |
|---|---|
| Epic | TV2H |
| Isin | GB00BDHF5D62 |
| Industry | Closed End Investments |
| Latest share price | 37.50p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £8.83 | Debt ratio | n/a |
| Shares in issue | 23.55 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | 0.25p | Price to book value | n/a |
| Dividend yield | 0.5 | ROCE | |
| Dividend cover | -5.6 | EPS growth | |
| Earning per share | -1.4 | 52-week high / low | 36.50p / 54.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Final | 2024-10-03 | 2024-10-18 | 0.25p |
| Final | 2023-08-31 | 2023-09-29 | 1.25p |
| Final | 2022-09-01 | 2022-09-30 | 3.50p |
| Final | 2021-09-02 | 2021-09-24 | 2.75p |
| Interim | 2020-09-03 | 2020-09-25 | 2.50p |
| Company name | Thames Ventures Vct 2 Healthcare |
|---|---|
| Address | 6th Floor, St. Magnus House, 3 Lower Thames Street, London, United Kingdom, EC3R 6HD |
| Telephone | +44 (0)20 7416 7780 |
| Website | www.downing.co.uk |
| Director | Position |
|---|---|
| Sir Aubrey Brocklebank | Chairman |
| Mr Chris Allner | Non-Executive Director |
| Mr Steven Clarke | Non-Executive Director |
| Dr Andrew Mackintosh | Non-Executive Director |
| Mr Lord Flight | Senior Independent Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/03/24 | 31/03/23 | 31/03/22 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | |||
| Total non-current assets | |||
| Inventory / work in progress | |||
| Trade and other receivables | |||
| Cash and equivalents | 10.46 | 6.08 | 2.48 |
| Other current assets and asset held for resale | |||
| Total of all assets | 41 | 51.75 | 19.06 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | |||
| Long term liabilities | |||
| Other liabilites / pension etc | |||
| Total of all liabilities | 0.61 | 1.21 | 0.31 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 40.39 | 50.53 | 18.75 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | |||
| Minority interests | n/a | n/a | n/a |
| Retained earnings | |||
| Share premium account | 1.4 | n/a | 8.59 |
| Total equity |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | 0.05 | 0.28 | 0.02 |
| Operating profit | -0.96 | -0.88 | -0.31 |
| Pre-tax profit | -0.96 | -0.88 | -0.31 |